SCHEMBL3013852

SCHEMBL3013852

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccccc4Cl)CC3)n2)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.40
MAPT P10636 5/20 0.38
GAA P10253 1/20 0.37
LMNA P02545 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
RAB9A P51151 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 5/20 0.36
MAPK1 P28482 1/20 0.36
KCNQ1 P51787 1/20 0.36
FAAH O00519 1/20 0.36
EPHX2 P34913 1/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
USP2 O75604 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007603 0.94 CTSS (0.38) CTSSMAPTLMNASMN1; SMN2RAB9A
SCHEMBL3003638 0.93 CTSS (0.40) CTSSMAPTGAALMNASMN1; SMN2
SCHEMBL3016184 0.92 SMN1; SMN2 (0.37) MAPTLMNASMN1; SMN2RAB9ATDP1
SCHEMBL3013303 0.92 MAPT (0.37) CTSSMAPTLMNASMN1; SMN2RAB9A
SCHEMBL3018577 0.91 CTSS (0.40) CTSSMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL3007519 0.90 MAPT (0.37) CTSSMAPTLMNASMN1; SMN2RAB9A
SCHEMBL3013075 0.90 MAPT (0.40) MAPTLMNASMN1; SMN2RAB9ATDP1
SCHEMBL15671698 0.90 MAPT (0.36) CTSSMAPTLMNASMN1; SMN2RAB9A
SCHEMBL3009127 0.90 CTSS (0.42) CTSSMAPTLMNATDP1USP2
SCHEMBL3011425 0.89 MAPT (0.39) MAPTLMNASMN1; SMN2RAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885MAPT 18/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.